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Abstract
Brief psychotic disorder (BPD) is a relatively rare representative of psychotic disorders. Structural brain abnormalities in 
BPD are not known. We compared 30 patients with BPD and 30 matched healthy controls using high-resolution structural 
T1-weighted magnetic resonance imaging (MRI). We performed cortical/subcortical reconstruction and volumetric segmen-
tation using FreeSurfer v6.0. Results revealed that the caudal/rostral middle frontal cortex, superior frontal cortex, and the 
frontal pole were significantly smaller in patients with BPD compared to controls. The number of lifetime psychotic episodes 
negatively correlated with caudal middle frontal and frontal pole volumes. These results indicate structural abnormalities of 
the frontal cortex in BPD, which are associated with the number of psychotic relapses.
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Introduction
Mounting evidence from research conducted over the past 
decades suggests that schizophrenia is characterized by 
multifocal cortical and subcortical structural abnormalities 
(Fornito et al. 2009; Haijma et al. 2013; Honea et al. 2005; 
Shepherd et al. 2012; Wright et al. 2000). Although early 
meta-analyses indicated smaller mean cerebral volume, ven-
tricular enlargement, and regional volume reductions in the 
medial-temporal cortex (hippocampus/amygdala, parahip-
pocampal region) in patients with schizophrenia relative to 
healthy control subjects (Wright et al. 2000), more recent 
analyses uncovered grey matter reductions in an extended 
network including frontal, temporal, thalamic, and striatal 
regions (Fornito et al. 2009).
Much less is known about potential brain anomalies in 
brief psychotic disorder (BPD), a rare representative of 
psychotic disorders (Marneros and Pillmann 2004). Some 
symptoms of BPD are similar to those seen in schizophrenia 
(delusion, hallucinations, disorganized speech, and grossly 
disorganized or catatonic behavior), but clinicians often 
observe a sudden onset and a short duration of symptoms 
(at least 1 day, but less than 1 month) (American Psychiat-
ric Association 2013). Most of the patients with BPD make 
a full recovery, their psychosocial functions are relatively 
spared, and negative symptoms are missing or minimal. 
Meta-analytic evidence suggests a better long-term prog-
nosis of BPD compared with remitted first-episode schizo-
phrenia (Fusar-Poli et al. 2016a). The prospective diagnostic 
stability of BPD is clinically acceptable, but less stable than 
that of schizophrenia (Fusar-Poli et al. 2016b). Interestingly, 
several individuals with Brief Limited Intermittent Psychotic 
Symptoms (BLIPS), a high-risk state of long-lasting psy-
chosis, meet the criteria of Acute and Transient Psychotic 
Disorder (ATPD). Many of these patients develop schizo-
phrenia-spectrum disorders, and therefore BPD is being used 
to identify patients at risk of developing persistent psychoses 
(Fusar-Poli et al. 2017a, b, c; Singh et al. 2004). The etiol-
ogy and epidemiology of BPD are not clear, although severe 
acute stress, trauma, recent childbirth, immigrant status, and 
living in a developing country are among the risk factors 
(Castagnini and Fusar-Poli 2017).
The paucity of neurobiological findings in BPD is a major 
shortcoming in the literature (Castagnini and Fusar-Poli 
2017; Malhotra et al. 2019). Therefore, to explore structural 
brain abnormalities in BPD, we recruited 30 patients with 
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BPD in clinical remission and 30 matched healthy controls. 
Based on previous results from other psychotic disorders 
(Fornito et al. 2009; Haijma et al. 2013; Honea et al. 2005; 
Shepherd et al. 2012; Wright et al. 2000), we hypothesized 
that patients with BPD exhibit smaller regional volumes in 
neocortical and limbic areas with special reference to frontal 
and temporal regions, including the hippocampal formation, 
relative to control participants. In addition, we explored the 
correlations between regional brain volumes and clinical 
characteristics (illness duration, number of lifetime psy-
chotic episodes, and cumulative antipsychotic medication).
Methods and materials
Participants
We enrolled 30 outpatients with BPD and 30 healthy control 
subjects matched for age, gender, education, general psycho-
social functions, and body-mass index (BMI) (Table 1). The 
study was coordinated in the Nyírő Gyula National Institute 
of Psychiatry and Addictions (NIPA) (Budapest, Hungary, 
2013–2019), and the BPD patients were recruited at the 
psychosis outpatient unit of this Institute. For the clinical 
assessment, we used the Structured Clinical Interview for 
DSM-5 Disorders—Clinician Version (SCID-5-CV) (First 
et al. 2016), the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al. 1987), and the WHO Disability Assess-
ment Schedule (WHODAS 2.0) of the DSM-5 (American 
Psychiatric Association 2013). BPD was diagnosed accord-
ing to the DSM-5 criteria: “A. Presence of one (or more) of 
the following symptoms. At least one of these must be (1), 
(2), or (3): 1. delusions, 2. hallucinations, 3. disorganized 
speech (e.g., frequent derailment or incoherence), 4. grossly 
disorganized or catatonic behavior. (Note: Do not include a 
symptom if it is a culturally sanctioned response.); B. Dura-
tion of an episode of the disturbance is at least 1 day but less 
than 1 month, with eventual full return to premorbid level of 
functioning. C. The disturbance is not better explained by 
major depressive or bipolar disorder with psychotic features 
or another psychotic disorder such as schizophrenia or cata-
tonia and is not attributable to the physiological effects of 
a substance (e.g., a drug of abuse, a medication) or another 
medical condition.” (American Psychiatric Association 
2013). Family history and premorbid functioning were 
rated on the OPCRIT + system (Rucker et al. 2011). We 
used the WAIS-III for the assessment of general intellectual 
and cognitive functioning (Wechsler 1997). The scales and 
Table 1  Demographic and 
clinical characteristics
Data are mean (standard deviation) except for the male/female ratio and the number of tobacco smokers. 
The two groups did not differ in gender ratio, age, education, BMI, and WHODAS 2.0 (ps > 0.5)
Brief psychotic disorder 





Age (years) 39.6 (7.2) 39.1 (7.0)
Education (years) 12.5 (4.8) 12.3 (3.9)
Wechsler Adult Intelligence Scale-III (IQ) 106.4 (12.5) 105.9 (11.7)
Number of tobacco smokers 11 11
Family history of psychiatric disorders
 Any psychiatric disorder 6 (20%) 7 (23.3%)
 Schizophrenia 0 0
 Affective disorder 3 (10%) 4 (13.3%)
 Body-mass index (BMI) 25.3 (3.2) 25.2 (3.7)
 WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) 13.1 (4.0) 13.3 (3.9)
Premorbid functioning
 Poor premorbid work adjustment 4 (13.3%) –
 Poor premorbid social adjustment 4 (13.3%) –
 Premorbid personality disturbance 6 (20%)
 Duration of illness (years) 12.5 (6.6) –
 Number of lifetime psychotic episodes 4.5 (2.9) –
Positive and Negative Syndrome Scale (PANSS)
 Positive 8.7 (2.7) –
 Negative 8.1 (3.0) –
 General 19.7 (5.3) –
 Lifetime antipsychotic dose-years 4.6 (2.3) –
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interviews were administered by trained clinical psycholo-
gists or psychiatrists. The interrater reliability values for the 
clinical scales were very good or excellent (Fleiss’ 휅  > 0.8).
We applied the following exclusion criteria: neurological 
disorders, history of personality disorders and mental dis-
orders other than BPD, evidence of head injury and trauma 
based on self-reports and medical records, and lifetime psy-
choactive substance misuse confirmed by the clinical history 
or by a urine test. There was no evidence of brain injury on 
the MRI scans (e.g., encephalomalacia). All patients were 
in clinical remission according to the Andreasen-criteria 
(Andreasen et al. 2005). Eight patients received second-
generation antipsychotic medications at the time of testing 
[olanzapine, quetiapine, and aripiprazole; chlorpromazine-
equivalent dose: 268 mg/day (SD = 194.3)] (Leucht et al. 
2015). We gathered data on the lifetime use of antipsy-
chotics by reviewing the comprehensive inpatient and out-
patient medical records. The lifetime use of antipsychotic 
medications was defined as the dose-years of a daily dose 
of 100 mg chlorpromazine equivalent (Husa et al. 2014). 
Given that most of the patients (n = 28) received second-
generation antipsychotics during their previous treatments, 
we did not calculate first- and second-generation drugs sepa-
rately. The study was approved by the Hungarian Scientific 
and Research Committee of the Medical Research Council, 
Budapest, Hungary. All participants gave written informed 
consents.
Structural brain imaging
T1-weighted, high-resolution scans were obtained at 
the imaging facility of the NIPA (Budapest) (Philips 
Achieva 3 T scanner, MPRAGE [magnetization-prepared 
rapid acquisition gradient echo], 3D sagittal acquisition, 
square field of view (FOV) = 256 mm, acquisition matrix: 
256 × 256, voxel size: 1 × 1 × 1  mm3, TI = 900 ms, TE 
(shortest) = 3.16 ms, flip angle: 9 degrees, no fat sup-
pression, full k space, no averages, acquisition time: 
6 min and 50 s, acceleration factor: 2). Image process-
ing was performed with Free-Surfer v6.0 (Athinoula A. 
Martinos Center for Biomedical Imaging). An extensively 
used, standard, and open protocol was implemented, as 
described in detail in several previous studies (https ://
surfe r.nmr.mgh.harva rd.edu/.) (Fischl 2012). All scans 
were visually inspected for motion artifacts before Free-
Surfer analysis. No scans had to be excluded because of 
motion artifacts. Brain regions were defined according to 
the Desikan-Killiany atlas (Desikan et al. 2006). In addi-
tion to intracranial volume and total gray/white matter 
volume, this atlas enables the measurement of 32 regional 
cortical volumes and 8 subcortical volumes. To minimize 
the number of variables (type I errors due to multiple 
comparisons), the volumes of each brain region in the left 
and right hemisphere were summed, and the total volume 
of each region (altogether 43 variables) was included in 
the statistical analysis.
Statistical analysis
We used STATISTICA 13.0 (Tibco, Palo Alto) and JASP 
(version 0.9.2., JASP Team) softwares for data analysis. 
Means and standard deviations were calculated for the 
variables of interest (regional brain volumes). We applied 
Kolmogorov–Smirnov tests (normality of distribution) and 
Levene’s tests (homogeneity of variance). One-way analyses 
of variance (ANOVAs) were performed on each regional 
brain volume to compare patients with BSD and healthy 
controls. The ANOVAs were repeated using a Bayesian 
approach. Pearson’s product–moment correlation coeffi-
cients (rs) were calculated between brain volumes and clini-
cal characteristics. To test the potential confounding and the 
modulating effect of age, education, social and occupational 
status, clinical symptoms, and BMI, analyses of covariance 
(ANCOVAs) were used. To minimize the likelihood of type 
I errors, multiple comparisons were corrected with the Ben-
jamini–Hochberg False Discovery Rate (FDR) method. The 
level of statistical significance was set at   < 0.05.
Results
Differences in brain volumes
Table 2 depicts the regional brain volumes in patients with 
BPD and healthy control subjects. We found significantly 
smaller regional brain volumes in patients with BPD rela-
tive to control subjects in the caudal middle frontal region 
[F(1,58) = 9.10, p < 0.005,  BF10 = 10.0], rostral middle fron-
tal region [F(1,58) = 14.19, p < 0.001,  BF10 = 68.9], supe-
rior frontal cortex [F(1,58) = 12.38, p < 0.002,  BF10 = 35.4], 
and the frontal pole [F(1,58) = 14.33, p < 0.001  BF10= 72.7]. 
There were no significant differences in the remaining brain 
areas (ps > 0.2,  BF10 < 1) (Table 2). The results remained 
the same when total brain volume, age, education, BMI, 
PANSS, and SOFAS scores were included separately in the 
analyses as covariates. There were no significant differences 
between male and female patients with BSD (p > 0.5).
Brain volumes and clinical characteristics
There were no significant correlations between brain vol-
umes, PANSS, lifetime antipsychotic dose-years, duration of 
illness in years, and age (− 0.2 < rs < 0.2, ps > 0.2). We found 
no significant differences between medicated (n = 8) and 
unmedicated (n = 22) BSD patients (p > 0.5). The number of 
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lifetime psychotic episodes negatively correlated with caudal 
middle frontal volumes (r = − 0.81, p < 0.001) and frontal 
pole volumes (r = − 0.61, p < 0.001) (Fig. 1.).
Table 2  Regional brain volumes in patients with brief psychotic disorder and healthy control subjects
Data  (mm3) are mean (standard deviation)
*Significant between-group differences (FDR corrected p values are shown in parentheses)
Bilateral brain region Brief psychotic disorder (n = 30) Healthy controls (n = 30) F p d
Intracranial volume 1,456,552.3 (29,746.3) 1,457,125.1 (28,421.5) 0.01 0.94 0.02
Cortical gray volume 497,428.6 (6370.1) 497,834.3 (6243.7) 0.06 0.80 0.07
Cortical white matter 503,472.6 (9170.6) 503,684.9 (9003.4) 0.01 0.93 0.02
Caudal anterior cingulate 4320.0 (270.5) 4380.2 (254.3) 0.78 0.38 0.23
Caudal middle frontal* 13,173.1 (780.2) 13,730.5 (650.7) 9.10 0.003 (0.03) 0.80
Cuneus 6310.1 (260.3) 6328.1 (257.5) 0.07 0.79 0.07
Entorhinal 3861.5 (148.3) 3858.7 (146.4) 0.005 0.94 0.02
Fusiform 20,205.4 (628.5) 20,194.1 (631.3) 0.005 0.94 0.02
Inferior parietal 29,778.4 (763.2) 29,883.7 (758.5) 0.29 0.59 0.14
Inferior temporal 22,540.2 (602.2) 22,560.6 (597.0) 0.02 0.89 0.03
Lateral occipital 24,570.4 (554.6) 24,563.6 (559.3) 0.002 0.96 0.01
Lateral orbital frontal 15,700.5 (649.8) 15,830.0 (660.2) 0.59 0.47 0.20
Lingual 14,111.2 (632.5) 14,104.9 (641.0) 0.001 0.97 0.01
Medial orbital frontal 10,835.6 (257.7) 10,947.3 (249.4) 2.91 0.09 0.45
Middle temporal 24,680.7 (597.3) 24,520.6 (601.0) 1.07 0.31 0.27
Parahippocampal 4597.0 (245.7) 4621.5 (239.2) 0.15 0.70 0.10
Paracentral 7760.3 (281.2) 7810.0 (235.4) 0.55 0.46 0.20
Pars opercularis 9554.6 (392.9) 9570.5 (380.0) 0.03 0.87 0.04
Pars orbitalis 4967.3 (202.5) 5074.6 (204.5) 4.17 0.05 0.52
Pars triangularis 8237.7 (246.3) 8300.7 (234.8) 1.03 0.31 0.27
Pericalcarine 4100.6 (270.4) 4150.6 (257.3) 0.54 0.47 0.19
Postcentral gyrus 19,663.5 (516.2) 19,574.1 (464.9) 0.50 0.48 0.19
Posterior cingulate 6762.6 (340.0) 6890.9 (325.5) 2.23 0.14 0.38
Precentral 27,670.3 (645.4) 27,690.2 (632.6) 0.01 0.90 0.03
Precuneus 21,055.1 (464.3) 21,198.7 (496.2) 1.34 0.25 0.30
Rostral anterior cingulate 5103.8 (250.2) 5178.5 (246.3) 1.36 0.25 0.30
Rostral middle frontal* 32,868.0 (768.8) 33,554.3 (691.6) 14.19 0.0004 (0.009) 0.95
Superior frontal* 44,955.0 (682.3) 45,541.2 (605.9) 12.38 0.0009 (0.01) 0.93
Superior temporal 28,452.4 (605.6) 28,500.3 (614.2) 0.09 0.76 0.08
Supramarginal 22,430.2 (663.5) 22,501.9 (657.2) 0.18 0.68 0.11
Frontal pole* 1350.7 (123.6) 1467.6 (115.3) 14.33 0.0004 (0.009) 0.98
Temporal pole 5200.4 (203.3) 5194.5 (208.5) 0.01 0.91 0.03
Transverse temporal 2190.5 (205.5) 2194.7 (204.3) 0.006 0.94 0.02
Insula 17,440.0 (458.0) 17,493.3 (446.2) 0.21 0.65 0.12
Lateral ventricles 13,002.6 (962.0) 12,945.5 (836.1) 0.06 0.81 0.07
Cerebellum 119,445.4 (3890.6) 119,654.4 (3791.0) 0.04 0.83 0.06
Thalamus 15,022.3 (376.2) 15,011.4 (380.0) 0.01 0.91 0.03
Caudate 7246.1 (218.3) 7220.0 (209.4) 0.22 0.64 0.12
Putamen 10,315.3 (296.3) 10,295.6 (301.7) 0.07 0.80 0.07
Pallidum 3235.1 (247.4) 3194.7 (265.9) 0.37 0.55 0.16
Hippocampus 8867.3 (429.3) 9001.4 (355.5) 1.73 0.19 0.34
Amygdala 3793.2 (345.3) 3760.2 (352.2) 0.13 0.71 0.10
Accumbens 1343.3 (299.6) 1332.0 (265.0) 0.02 0.88 0.04
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Discussion
We observed a selective volume reduction in the frontal 
cortex in BPD, including the caudal/ rostral middle frontal, 
superior frontal, and frontal polar regions. Smaller frontal 
volumes were associated with one of the most important 
clinical features of BPD, that is, the number of recurrent 
psychotic episodes without conversion to schizophrenia or 
other long-lasting psychotic disorders. Certainly, correla-
tion analyses do not provide information on the direction of 
causality. It is not clear whether a pre-existing decrease in 
frontal volumes predisposes to recurrent psychotic episodes, 
or frequent psychotic breakdowns result in cortical volume 
loss.
The results of the present study are different from that 
documented in schizophrenia (Fornito et al. 2009; Haijma 
et al. 2013; Honea et al. 2005; Shepherd et al. 2012; Wright 
et al. 2000): we did not find smaller volumes in temporal, 
parietal, subcortical, medio-temporal, and other limbic 
regions in BPD. Given the paucity of neuroimaging stud-
ies in BPD, comparisons with previous results are difficult. 
Early computed tomography (CT) studies from cycloid psy-
chosis, which is characterized by short psychotic episodes 
that does not necessarily fit into any DSM-5 category, pro-
vided inconsistent results regarding ventricular abnormali-
ties (Hoffler et al. 1997; Franzek et al. 1996). It is possible 
that circumscribed frontal alterations in BPD are a "tip of the 
iceberg” phenomenon, and a more extensive volume reduc-
tion could be detected in a larger sample of BPD patients. 
Methodological differences (e.g., FreeSurfer regional volu-
metry vs. voxel-based morphometry) are also critical, which 
may lead to the heterogeneity of results (Honea et al. 2005; 
van Erp et al. 2018). In an extensive meta-analysis with 
standardized FreeSurfer methodology, including thousands 
of patients with schizophrenia and controls from 39 cent-
ers, van Erp et al. (2018) demonstrated a widespread cor-
tical thinning in patients, with the largest negative effect 
sizes in bilateral fusiform, temporal (inferior, middle, and 
superior), and left superior frontal gyri, right pars oper-
cularis, and bilateral insula. Moreover, schizophrenia is 
associated with a progressive loss of cortical gray matter, 
and this reduction may be due to antipsychotic treatment, 
Fig. 1  Correlations between frontal volumes  (mm3) and the number of lifetime psychotic episodes in patients with brief psychotic disorder 
(BPD)
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especially in the case of first-generation drugs (Haijma 
et al. 2013; Fusar-Poli et al. 2013; Vita et al. 2015; Olabi 
et al. 2011). Honea et al. (2005) concluded that brain loss in 
schizophrenia may be explained by a combination of early 
neurodevelopmental processes and illness progression. The 
pathophysiology of progressive changes in brain structure 
is unknown. In addition to the negative effect of high-dose 
first-generation antipsychotics, intrinsic mechanisms of ill-
ness progression (e.g., glutamatergic dysfunction, decreased 
neurotrophic factors, and neuroinflammation) may also play 
a role (Bauer and Teixeira 2019). It is unclear whether these 
schizophrenia-related mechanisms are also implicated in 
BPD. By reviewing data from electrophysiology and brain 
metabolism, Malhotra et al. (2019) concluded that acute 
and transient psychoses are characterized by hyperarousal 
and hypermetabolism, whereas schizophrenia is associated 
with hypoarousal and hypometabolism. Increased peripheral 
inflammatory markers have also been detected in transient 
psychosis (Malhotra et al. 2019). In addition, we found evi-
dence for a circumscribed volume loss in the frontal cortex, 
which did not correlate with illness duration or cumulative 
lifetime antipsychotic use in BPD. It is important to bear in 
mind that the present study was cross-sectional, and, there-
fore, our data did not provide direct evidence of progres-
sive brain changes in BPD. In addition, separate groups of 
patients with recent-onset BPD and schizophrenia were not 
included in this study, and the direct comparison of these 
disorders is not possible.
The most important limitation of the present study is the 
small sample size. Therefore, the results must be replicated 
in a large sample from multiple clinical centers. Due to the 
small sample size and the issue of multiple comparisons 
(type I errors), we did not conduct separate analyses for the 
left and right hemispheres. Another limitation is that we did 
not apply structured clinical interviews for personality disor-
ders. It is a relevant and important issue because the preva-
lence of personality disorders is high in acute and transient 
psychoses (Jorgensen et al. 1996), and it may affect brain 
structure, especially in the case of schizotypal and border-
line personality disorder. However, structural abnormalities 
in the frontal cortex are not characteristic for schizotypal 
(Fervaha and Remington 2013) and borderline personality 
disorder (Kimmel et al. 2016).
Prefrontal dysfunctions are probably the most widely 
researched area in psychotic disorders, which may be impli-
cated in the developmental and neurocognitive mechanism of 
psychosis (e.g., executive dysfunctions, abnormal self-mon-
itoring, and social-cognitive impairments) (Cannon 2015; 
Tan et al. 2009; Sakurai and Gamo 2019). The main conclu-
sion of the present study is that prefrontal dysfunctions are 
also important in BPD. Future studies should explore the 
functional, neuropsychological, and neurochemical corre-
lates of these deficits. These multidisciplinary investigations 
are warranted because of the severe unmet needs of patients 
with short-lived psychotic episodes. For example, in a large 
sample of patients with a first index diagnosis of acute and 
transient psychosis, a 8-year follow-up study indicated that 
almost two-third of the patients (61.3%) retained the index 
diagnosis, whereas the remaining individuals developed 
persistent psychotic disorders (Rutigliano et al. 2018). The 
majority of individuals suffering from transient psychosis 
are invisible for high-risk and early intervention services, 
despite the fact that the clinical and psychosocial outcomes 
are severe, and clinical treatment approaches are heteroge-
neous and not satisfactory (Minichino et al. 2019). Thus, a 
more detailed investigation and characterization of the neu-
rological phenotype and mechanisms are necessary to refine 
the diagnosis and treatment strategy in patients with BPD.
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